{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:49:54Z","timestamp":1789094994704,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.neuropharm.2020.108333","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T16:54:03Z","timestamp":1600793643000},"page":"108333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"special_numbering":"C","title":["Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator"],"prefix":"10.1016","volume":"181","author":[{"given":"Alison L.","family":"Althaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Ackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel M.","family":"Belfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana M.","family":"Kazdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Modgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco G.","family":"Salituro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Robichaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108333_bib1","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1073\/pnas.1403285111","article-title":"Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors","volume":"111","author":"Abramian","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2020.108333_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.yebeh.2016.12.024","article-title":"The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication","volume":"68","author":"Althaus","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2020.108333_bib3","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib4","doi-asserted-by":"crossref","first-page":"100207","DOI":"10.1016\/j.ynstr.2019.100207","article-title":"Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor","volume":"12","author":"Belelli","year":"2019","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.neuropharm.2020.108333_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fnins.2016.00269","article-title":"Parkinson's disease and neurodegeneration: GABA-collapse hypothesis","volume":"10","author":"Blaszczyk","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/ejn.13595","article-title":"Neurobiological bases of autism-epilepsy comorbidity: a focus on excitation\/inhibition imbalance","volume":"47","author":"Bozzi","year":"2018","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.neuron.2015.03.042","article-title":"The GABAA receptor as a therapeutic target for neurodevelopmental disorders","volume":"86","author":"Braat","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108333_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-013-3276-5","article-title":"Neurosteroid interactions with synaptic and extrasynaptic GABAA receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability","volume":"230","author":"Carver","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1152\/jn.00539.2013","article-title":"EEG-beta\/gamma spectral power elevation in rat: a translatable biomarker elicited by GABA(Aalpha2\/3)-positive allosteric modulators at nonsedating anxiolytic doses","volume":"113","author":"Christian","year":"2015","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib10","article-title":"Exploratory trial results for SAGE-547 in essential tremor","volume":"78","author":"Ellenbogen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(99)01318-8","article-title":"Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders","volume":"20","author":"Gasior","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib13","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1523\/JNEUROSCI.5663-11.2012","article-title":"Benzodiazepines modulate GABAA receptors by regulating the preactivation step after GABA binding","volume":"32","author":"Gielen","year":"2012","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108333_bib14","first-page":"254","volume":"vol. 4","author":"Gironell","year":"2014"},{"key":"10.1016\/j.neuropharm.2020.108333_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.108333_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00000542-197503000-00017","article-title":"Steroid anesthetics","volume":"42","author":"Gyermek","year":"1975","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eplepsyres.2017.05.001","article-title":"Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models","volume":"134","author":"Hammond","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2020.108333_bib18","doi-asserted-by":"crossref","first-page":"15327","DOI":"10.1038\/s41598-017-15609-w","article-title":"The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model","volume":"7","author":"Hawkins","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108333_bib19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0026-895X(25)09842-6","article-title":"Correlation of neuroactive steroid modulation of [35S]t-butylbicyclophosphorothionate and [3H]flunitrazepam binding and gamma-aminobutyric acidA receptor function","volume":"46","author":"Hawkinson","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib20","series-title":"SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies","author":"Hoffmann","year":"2019"},{"key":"10.1016\/j.neuropharm.2020.108333_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneumeth.2007.11.028","article-title":"An automated system for intracellular and intranuclear injection","volume":"169","author":"Hogg","year":"2008","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2020.108333_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuropharm.2008.07.050","article-title":"Conserved site for neurosteroid modulation of GABA A receptors","volume":"56","author":"Hosie","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature05324","article-title":"Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites","volume":"444","author":"Hosie","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108333_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pharmthera.2007.03.011","article-title":"Neurosteroid binding sites on GABAA receptors","volume":"116","author":"Hosie","year":"2007","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108333_bib25","doi-asserted-by":"crossref","first-page":"18595","DOI":"10.1073\/pnas.1204994109","article-title":"Benzodiazepine treatment induces subtype-specific changes in GABA(A) receptor trafficking and decreases synaptic inhibition","volume":"109","author":"Jacob","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2020.108333_bib26","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.2174\/1381612821666150914121624","article-title":"GABA receptors: pharmacological potential and pitfalls","volume":"21","author":"Jembrek","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2020.108333_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1471-4892(02)00015-2","article-title":"GABA(A) receptor function and pharmacology in epilepsy and status epilepticus","volume":"3","author":"Jones-Davis","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108333_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression","volume":"32","author":"Kanes","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib30","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.1073\/pnas.0506653102","article-title":"Phospho-dependent binding of the clathrin AP2 adaptor complex to GABAA receptors regulates the efficacy of inhibitory synaptic transmission","volume":"102","author":"Kittler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108333_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0959-4388(03)00064-3","article-title":"Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition","volume":"13","author":"Kittler","year":"2003","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nsmb.3477","article-title":"-receptor chimera reveal new endogenous neurosteroid-binding sites","volume":"24","author":"Laverty","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib33","volume":"vol. 8","author":"L\u00fcscher","year":"2019"},{"key":"10.1016\/j.neuropharm.2020.108333_bib34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108333_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-199223030-00003","article-title":"Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs","volume":"23","author":"Mandema","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2020.108333_bib36","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-Hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-Aminobutyric Acid)A receptor","volume":"60","author":"Martinez-Botella","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108333_bib37","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1021\/acs.jmedchem.5b00032","article-title":"Neuroactive steroids. 1. Positive allosteric modulators of the (\u03b3-Aminobutyric acid) A receptor: structure-activity relationships of heterocyclic substitution at C-21","volume":"58","author":"Martinez-Botella","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108333_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.bjp.0706550","article-title":"Differential behavioral effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys","volume":"147","author":"McMahon","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fendo.2018.00703","article-title":"A novel, synthetic, neuroactive steroid is effective at decreasing depression-like behaviors and improving maternal Care in preclinical models of postpartum depression","volume":"9","author":"Mel\u00f3n","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib40","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108333_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuropharm.2016.10.010","article-title":"Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism","volume":"113","author":"Modgil","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib42","first-page":"165","article-title":"Anxiety disorders and GABA neurotransmission: a disturbance of modulation","volume":"11","author":"Nuss","year":"2015","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2020.108333_bib43","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1152\/jn.2002.87.5.2624","article-title":"Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells","volume":"87","author":"Nusser","year":"2002","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2020.108333_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0006-8993(99)02151-4","article-title":"Propofol increases agonist efficacy at the GABA(A) receptor","volume":"852","author":"O'Shea","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108333_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","article-title":"GABAA receptor: positive and negative allosteric modulators","volume":"136","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABA A receptors: subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108333_bib47","doi-asserted-by":"crossref","first-page":"12220","DOI":"10.1074\/jbc.RA119.008875","article-title":"Metabotropic, but not allosteric, effects of neurosteroids on GABAergic inhibition depend on the phosphorylation of GABAA receptors","volume":"294","author":"Parakala","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108333_bib48","doi-asserted-by":"crossref","first-page":"91S","DOI":"10.1016\/S0952-8180(96)90021-5","article-title":"Steroid anesthetics: old compounds, new drugs","volume":"8","author":"Sear","year":"1996","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.neuropharm.2020.108333_bib49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.pmrj.2009.08.002","article-title":"Spastic hypertonia and movement disorders: pathophysiology, clinical presentation, and quantification","volume":"1","author":"Sheean","year":"2009","journal-title":"PM&R"},{"key":"10.1016\/j.neuropharm.2020.108333_bib50","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/1568026023393444","article-title":"Mapping of the benzodiazepine recognition site on GABA(A) receptors","volume":"2","author":"Sigel","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108333_bib51","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABA(A) receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108333_bib52","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/0024-3205(84)90159-0","article-title":"Convulsant potencies of tetrazoles are highly correlated with actions on GABA\/benzodiazepine\/picrotoxin receptor complexes in brain","volume":"35","author":"Squires","year":"1984","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib53","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1947601912440575","article-title":"Quantitative methods for assessing drug synergism","volume":"2","author":"Tallarida","year":"2011","journal-title":"Gene Canc."},{"key":"10.1016\/j.neuropharm.2020.108333_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1528-1157.2001.042suppl.3008.x","article-title":"GABAergic mechanisms in epilepsy","volume":"42","author":"Treiman","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108333_bib55","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/jpet.103.054510","article-title":"Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats","volume":"307","author":"Visser","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108333_bib56","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1124\/jpet.302.3.1158","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats","volume":"302","author":"Visser","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108333_bib57","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1124\/jpet.102.039610","article-title":"Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo","volume":"303","author":"Visser","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108333_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1124\/jpet.102.042341","article-title":"Mechanism-Based pharmacokinetic\/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations","volume":"304","author":"Visser","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108333_bib59","doi-asserted-by":"crossref","first-page":"i167","DOI":"10.1093\/bja\/aex369","article-title":"Role of GABAA receptor subtypes in the behavioural effects of intravenous general anaesthetics","volume":"119","author":"Weir","year":"2017","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2020.108333_bib60","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/j.1460-9568.2009.06716.x","article-title":"Role of GABAA receptors in the physiology and pharmacology of sleep","volume":"29","author":"Winsky-Sommerer","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108333_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamapsychiatry.2013.245","article-title":"Neurosteroids as therapeutic leads in psychiatry","volume":"70","author":"Zorumski","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108333_bib62","first-page":"1053","article-title":"Potential clinical uses of neuroactive steroids","volume":"3","author":"Zorumski","year":"2000","journal-title":"Idrugs : the investigational drugs journal"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:08:01Z","timestamp":1758438481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820304019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":62,"alternative-id":["S0028390820304019"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108333","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108333"}}